The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed ...
Stocktwits on MSN
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail
The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance ...
Walter Klemp, Chairman and CEO, announced significant progress on the MIRACLE Phase 3 pivotal trial for Annamycin, targeting second-line treatment of relapsed and refractory AML patients. The trial ...
Panelists discuss how the pathophysiology of acute myeloid leukemia has evolved from a single phenotype understanding to recognizing diverse genetic events that lead to transformation at the ...
SENTI-202 targets CD33 or FLT3, sparing EMCN, enhancing precision in treating hematologic malignancies like AML. Preliminary data shows high efficacy, with significant composite complete remission ...
Moleculin Biotech, Inc. announced that the World Health Organization has approved “naxtarubicin” as the non-proprietary name for its next-generation anthracycline, Annamycin, which is being developed ...
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...
Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma Anthracycline and cytarabine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results